))
Episode 30. Management of High-Risk Myeloma
Manage episode 376847685 series 3369804
İçerik Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
In this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies. Here are the key studies that we touched upon:
1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and PCL:
https://pubmed.ncbi.nlm.nih.gov/37315268/
2. Meta-analysis of >2500 patients with chromosome 1q21 abnormalities:
https://pubmed.ncbi.nlm.nih.gov/34092058/
3. Predicting ultra-high risk myeloma by molecular profiling (including SKY92 GEP signature):
https://pubmed.ncbi.nlm.nih.gov/32157174/
4. French data on adverse prognostic impact of del(1p32):
https://pubmed.ncbi.nlm.nih.gov/36375118/
5. S1211 study: The first high-risk enrichment RCT in myeloma (VRD vs Elo-VRD):
https://pubmed.ncbi.nlm.nih.gov/33357482/
6. Outcome of “double-hit” patients in MASTER and Dara-VRD arm of GRIFFIN trial:
https://ashpublications.org/blood/article/140/Supplement%201/10144/488521
7. Impact of Auto-Transplant on decreasing MRD burden in high-risk myeloma (including double-hits):
https://pubmed.ncbi.nlm.nih.gov/35731911/
8. Preliminary results from GMMG-CONCEPT trial in high-risk myeloma:
47 bölüm
Paylaş
